Adults with refractory chronic cough who received twice-daily camlipixant had decreases in cough frequency and better scores ...

These challenges may foster abbreviated evaluations, with some clinicians prematurely diagnosing “unexplained chronic cough” and “refractory chronic cough” in patients who have not been ...

The most common causes of chronic cough include gastroesophageal reflux disease (GERD), asthma, and postnasal drip (also ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Announced positive topline data from the Phase 2a RIVER trial in patients with refractory chronic cough (RCC), making Haduvio the first therapy in clinical development to show benefit in patients ...

Announced positive topline data from the Phase 2a RIVER trial in patients with refractory chronic cough (RCC), making Haduvio the first therapy in clinical development to show benefit in patients ...

Refractory chronic cough, affecting approximately 2-3 million individuals in the U.S., is persistent and remains untreated as no therapies are approved, causing serious complications and economic ...

At the moment there are no approved therapies for suppressing refractory chronic cough, defined as lasting for eight weeks or more, which is estimated to affect somewhere between 5% and 10% of ...